--- title: "Amphastar Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 183.9 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295151361.md" datetime: "2026-08-06T22:18:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295151361.md) - [en](https://longbridge.com/en/news/295151361.md) - [zh-HK](https://longbridge.com/zh-HK/news/295151361.md) generator: "portal-rs" --- # Amphastar Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 183.9 M Revenue: As of FY2026 Q2, the actual value is USD 183.9 M, beating the estimate of USD 179.92 M. EPS: As of FY2026 Q2, the actual value is USD 0.67, beating the estimate of USD 0.37. EBIT: As of FY2026 Q2, the actual value is USD 44.12 M. #### Net Revenues Amphastar Pharmaceuticals, Inc. reported net revenues of $183.9 million for the three months ended June 30, 2026, marking an increase of 5% compared to $174.4 million in the prior year period. For the six months ended June 30, 2026, net revenues were $355.074 million, up from $344.942 million in the same period of 2025. #### Segment Revenue Breakdown (Three Months Ended June 30, 2026 vs. 2025) - BAQSIMI® revenue was $45.503 million, a decrease of - $1.184 million or -3%, primarily due to a lower average selling price, partially offset by increased unit volumes. - Primatene MIST® revenue was $21.004 million, a decrease of - $1.876 million or -8%, attributed to the timing of customer purchases. - Epinephrine revenue was $15.854 million, a decrease of - $326 thousand or -2%, mainly due to increased competition for the multi-dose vial product, partially offset by increased demand for the pre-filled syringe. - Lidocaine revenue was $15.039 million, an increase of $40 thousand or 0%. - Glucagon revenue was $11.905 million, a decrease of - $8.697 million or -42%, driven by a lower average selling price and decreased unit volumes from competition and a shift to ready-to-use products like BAQSIMI®. - Ipratropium bromide generated $8.411 million in revenue, following a successful launch in April 2026. - Other products generated $66.187 million, an increase of $13.121 million or 25%, driven by recently launched products such as iron sucrose and teriparatide, as well as increased phytonadione, sodium bicarbonate, and API sales. #### Net Income GAAP net income for the three months ended June 30, 2026, was $30.348 million, down from $31.030 million in the prior year period. For the six months ended June 30, 2026, GAAP net income was $36.768 million, compared to $56.315 million in the same period of 2025.Adjusted non-GAAP net income was $40.759 million for the three months ended June 30, 2026, slightly down from $40.893 million in the prior year. For the six months ended June 30, 2026, adjusted non-GAAP net income was $60.237 million, compared to $77.764 million in the prior year period. #### Gross Profit and Margin Gross profit for the three months ended June 30, 2026, was $93.470 million, an increase of $6.980 million or 8% from $86.490 million in the prior year. The gross margin improved to 50.8% of net revenues for the three months ended June 30, 2026, up from 49.6% in the prior year period. #### Operating Expenses (Three Months Ended June 30, 2026 vs. 2025) - Selling, distribution, and marketing expenses increased by $3.100 million or 30% to $13.335 million, primarily due to increased freight expense and marketing efforts for BAQSIMI®. - General and administrative expenses increased by $4.251 million or 30% to $18.242 million, mainly due to higher legal expenses, ERP system implementation costs, and salary expenses. - Research and development expenses increased by $2.084 million or 10% to $22.164 million, driven by higher clinical trial expenses for insulin pipeline products and salary expenses, partially offset by decreased material costs. #### Income from Operations Income from operations for the three months ended June 30, 2026, was $39.729 million, compared to $42.184 million for the same period in 2025. #### Non-Operating Expenses, Net Total non-operating expenses, net, for the three months ended June 30, 2026, was - $1.185 million, an improvement from - $2.849 million in the prior year, primarily due to foreign currency fluctuations and mark-to-market adjustments related to an interest rate swap contract. #### Cash Flow Cash flow provided by operating activities for the six months ended June 30, 2026, was $99.2 million. #### Unique Metrics and Operational Highlights Amphastar Pharmaceuticals, Inc. achieved the first annual net sales milestone for BAQSIMI® under its agreement with Eli Lilly & Company, with sales reaching $175.0 million for the contract year, triggering a $100.0 million payment to Lilly due in the third quarter of 2026.The company’s pipeline includes one abbreviated new drug application (ANDA) and one biosimilar insulin candidate filed with the FDA, targeting a combined market size exceeding $1.6 billion. Additionally, two biosimilar products in development target a market size over $3.5 billion, and three generic products in development target a market size over $1.2 billion. #### Outlook / Guidance Amphastar Pharmaceuticals, Inc. aims to build a diversified and innovative biopharmaceutical company, focusing on continued revenue growth, gross margin expansion, and successful new product launches. The company is advancing both its generic and proprietary development pipelines, including four recently in-licensed proprietary products targeting oncology, ophthalmology, and inflammatory/autoimmune conditions. This integrated business model is expected to position the company for long-term sustainable growth. ### Related Stocks - [AMPH.US](https://longbridge.com/en/quote/AMPH.US.md) ## Related News & Research - [Amphastar CFO William J. Peters melepas saham biasa senilai $183.826,4](https://longbridge.com/en/news/295579594.md) - [Amneal EVP, Chief Legal Officer Jason B. Daly sells USD 3.77 million in common shares](https://longbridge.com/en/news/295842115.md) - [Elanco director Michael J. Harrington buys 5,000 shares for $109,100](https://longbridge.com/en/news/295843350.md) - [Yarrow Bioscience files amended 8-K report on merger exchange ratio update](https://longbridge.com/en/news/295840217.md) - [MDWD: Q2 revenue fell, but guidance held as EscharEx and NexoBrid programs advanced and U.S. sales grew](https://longbridge.com/en/news/295796876.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**